BioMarin Pharmaceutical
BMRN
$88.63
Share price
-1.60%
Change (1 day)
-9.94%
Change (1 year)
Categories
P/S ratio for BioMarin Pharmaceutical (BMRN)
P/S ratio as of April 2024 (TTM): 7.07
According to BioMarin Pharmaceutical's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.0655. At the end of 2023 the company had a P/S ratio of 7.51.
P/S ratio history for BioMarin Pharmaceutical from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 7.51 | -18.18% |
| 2022 | 9.18 | 4.45% |
| 2021 | 8.79 | 2.68% |
| 2020 | 8.56 | -4.11% |
| 2019 | 8.92 | -12.33% |
| 2018 | 10.2 | -14.62% |
| 2017 | 11.9 | -6.55% |
| 2016 | 12.8 | -32.91% |
| 2015 | 19.0 | 5.92% |
| 2014 | 18.0 | -2.43% |
| 2013 | 18.4 | 48.85% |
| 2012 | 12.4 | 38.95% |
| 2011 | 8.90 | 12.36% |
| 2010 | 7.92 | 35.37% |
| 2009 | 5.85 | -2.4% |
| 2008 | 5.99 | -78.8% |
| 2007 | 28.3 | 58.38% |
| 2006 | 17.9 | -42.79% |
| 2005 | 31.2 | 41.13% |
| 2004 | 22.1 | -16.81% |
| 2003 | 26.6 | -2.43% |
| 2002 | 27.2 | -60.02% |
| 2001 | 68.1 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 2.25 | -68.15% | 🇫🇷 France |
 Ultragenyx RARE | 8.23 | 16.41% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | 0.5606 | -92.07% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | 3.04 | -56.91% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | 7.64 | 8.14% | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | 4.55 | -35.66% | 🇺🇸 USA |